GT Apeiron Therapeutics
http://www.apeiron-bio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GT Apeiron Therapeutics
BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate
Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- GT Apeiron Therapeutics